Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera Therapeutics stock plunged by more than 70% Tuesday after the Malvern biopharmaceutical firm said its lead experimental cancer therapy failed to meet its primary endpoint in late-stage clinical testing. The new drug candidate, called GC4419, is under development as a treatment for severe oral mucositis in patients with locally advanced head and neck cancer undergoing radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of severe oral mucositis, a condition… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2021 Category: Biotechnology Authors: John George Source Type: news

Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors. Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998. "Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 18, 2021 Category: American Health Authors: Rick Morgan Source Type: news

Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors. Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998. "Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2021 Category: Biotechnology Authors: Rick Morgan Source Type: news

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIR... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2021 Category: Pharmaceuticals Source Type: news

Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT ... Devices, Oncology Alpha Tau Medical, Alpha DaRT, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2021 Category: Pharmaceuticals Source Type: news

Medical College of Wisconsin hires CannonDesign for $100M cancer research center project
The Medical College of Wisconsin hired global firm CannonDesign for what it called Milwaukee ’s first research center dedicated to cancer therapies and treatments. That MCW Cancer Research Building was first announced in 2019 as an about $100 million, 150,000-square-foot facility. It would expand on the cancer research the Medical College is already doing at the Milwaukee Regional Medic al Center in Wauwatosa. Design work is to start this fall and will last into 2022, according to a Tuesday announcement… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 28, 2021 Category: American Health Authors: Sean Ryan Source Type: news

Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
SAN DIEGO, Sept. 22, 2021 -- (Healthcare Sales & Marketing Network) -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, ... Biopharmaceuticals, Oncology Kintara Therapeutics, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 22, 2021 Category: Pharmaceuticals Source Type: news

Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches  Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs.   Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abex...
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news

Telix applauds NCCN radiotracer update
Injection kit developer Telix applauded the National Comprehensive Cancer Network'...Read more on AuntMinnie.comRelated Reading: Telix, Kettering to research PSMA radiotracer Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2021 Category: Radiology Source Type: news

Gilead Sciences considered Atlanta, Durham before selecting Raleigh for 275 jobs
The maker of breakthrough HIV, hepatitis C and cancer therapies — as well as the Covid drug remdesivir — snagged nearly $10 million reimbursement incentive and more than $357,000 in community college training incentives from North Carolina. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 16, 2021 Category: American Health Authors: Lauren Ohnesorge Source Type: news

Cell therapy partnership between Bay Area biotechs offers hope to cancer patients
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Lauren Lawley Head Source Type: news

Heating Up CAR T Cells for Cancer Therapy
Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells. (Source: The Scientist)
Source: The Scientist - September 10, 2021 Category: Science Tags: Sponsored Article Source Type: news

B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
To Downsize Systems and Spread High-precision Irradiation Technology TOKYO, Sept. 9, 2021 -- (Healthcare Sales & Marketing Network) -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at i... Devices, Oncology, Radiology B dot Medical, proton therapy, compact proton cancer therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 9, 2021 Category: Pharmaceuticals Source Type: news

Telix, Kettering to research PSMA radiotracer
Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix'...Read more on AuntMinnie.comRelated Reading: Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 8, 2021 Category: Radiology Source Type: news

Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
David Miklos discusses recent advances in bispecific CAR-T therapy development. (Source: The Scientist)
Source: The Scientist - September 7, 2021 Category: Science Tags: Sponsored Webinars Source Type: news

RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
510(k) Device May Improve Targeted Delivery of Chemotherapy LOS ALTOS, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announc... Devices, Drug Delivery, Oncology, FDA RenovoRx, RenovoCath Delivery System, RenovoGem, RenovoTAMP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news

CV Safety Study of Cancer Therapy Attracts Attention CV Safety Study of Cancer Therapy Attracts Attention
Although the first global trial to compare the cardiovascular (CV) safety of two therapies for prostate cancer proved inconclusive, it was"a model for interdisciplinary collaboration" says investigator.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 31, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Review Eyes Nail Toxicities Related to Targeted Cancer Therapy Review Eyes Nail Toxicities Related to Targeted Cancer Therapy
The investigators found that paronychia and periungual pyogenic granulomas were the most common nail unit toxicities caused by targeted therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 24, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Lightpoint, Telix ink collaboration agreement
Luminescence imaging technology developer Lightpoint Medical has signed a collaboratio...Read more on AuntMinnie.comRelated Reading: Telix works with Merck on cancer therapies Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply Lightpoint announces new CEO Lightpoint gets CE Mark for Sensei device Lightpoint licenses molecular imaging technology (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 23, 2021 Category: Radiology Source Type: news

Telix works with Merck on cancer therapies
Telix Pharmaceuticals is entering into a collaboration with Merck for researc...Read more on AuntMinnie.comRelated Reading: Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply ARTMS, Telix produce PSMA-11 in cyclotron Telix files NDA for prostate cancer PET imaging agent RefleXion, Telix partner on high-risk cancer treatments (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 20, 2021 Category: Radiology Source Type: news

Navrogen raises $3M in venture capital financing to advance cancer therapy platform
The four-year-old company also converted more than $3 million in notes into equity. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 16, 2021 Category: Biotechnology Authors: John George Source Type: news

Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Cancer Therapy and Myocardial Dysfunction: 5 Things to Know Cancer Therapy and Myocardial Dysfunction: 5 Things to Know
An expert overview of some key aspects to preventing, monitoring, and managing cardiac dysfunction related to cancer therapy.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 26, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Novel imaging agent identifies biomarker for iron-targeted cancer therapies
(Society of Nuclear Medicine and Molecular Imaging) A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Cancer: Information theory to fight resistance to treatments
(Universit é de Gen è ve) A major challenge in cancer therapy is the adaptive response of cancer cells to targeted therapies. Although this adaptive response is theoretically reversible, such a reversal is hampered by numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. A team (UNIGE/HUG) has used information theory, in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2021 Category: International Medicine & Public Health Source Type: news

Scientists provide new insight on how to stop transcription of cancer cells
(University of California - Los Angeles Health Sciences) Findings could help pave the way for cancer therapies that target TAF12, potentially stopping transcription in cancer cells and helping decrease the growth of cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Homing Technology Delivers Therapy to Cancerous Bone
A clever approach to modifying already existing cancer therapies may be a game changer for treating metastatic breast cancer. (Source: The Scientist)
Source: The Scientist - July 19, 2021 Category: Science Tags: Sponsored Article Source Type: news

Swiss Researchers Develop a Multi-omic Tumor Profiler to Inform Clinical Decision Support and Guide Precision Medicine Therapy for Cancer Patients
New biomarkers for cancer therapies derived from the research could usher in superior clinical laboratory diagnostics that identify a patient’s suitability for personalized drug therapies and treatments In another advancement toward accurate precision medicine, Swiss researchers from the University Hospitals of Zurich and Basel, ETH Zurich, the University of Zurich, and pharmaceutical company Roche have […] The post Swiss Researchers Develop a Multi-omic Tumor Profiler to Inform Clinical Decision Support and Guide Precision Medicine Therapy for Cancer Patients appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - July 19, 2021 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Digital Pathology International Laboratory News Laboratory Pathology Laboratory Testing Molecular Diagnostics, Genetic Testing, Whole Gene Sequencing Precision Medicine anatomic pathology Cancer Cell clinical laboratory clinical patholog Source Type: news

NSF grant to advance research in cancer treatment
(Virginia Tech) As a form of cancer therapy, histotripsy uses ultrasound imaging to monitor treatments in real-time, making it noninvasive with minimal side effects. Thus far, histotripsy has shown promising results in clinical studies for liver cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples. (Source: The Scientist)
Source: The Scientist - July 16, 2021 Category: Science Tags: News & Opinion Source Type: news

Damon Runyon Cancer Research Foundation awards $4.8 million to rising investigators
(Damon Runyon Cancer Research Foundation) Damon Runyon Cancer Research Foundation has announced the 2021 recipients of the Damon Runyon Clinical Investigator award--six outstanding early career physician-scientists working to develop new cancer therapies under the mentorship of the nation's leading scientists and clinicians. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Antibiotic-Linked Antibody Attacks Cancer ’s Sinister Neighbor Cells
An unexpected and unprecedented finding may lead to improved cancer therapies. (Source: The Scientist)
Source: The Scientist - July 14, 2021 Category: Science Tags: Sponsored Article Source Type: news

PPIs Could Be Bad News for Oral Cancer Therapies PPIs Could Be Bad News for Oral Cancer Therapies
GIs may want to be mindful of prescribing PPIs for patients with cancer because they may adversely affect concomitant oral therapies.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 13, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Scientists discover nanoclusters effective for cancer in the second near-infrared synergy therapy
(Hefei Institutes of Physical Science, Chinese Academy of Sciences) As a minimally invasive method for cancer therapy at precise locations, NIR-induced photothermal therapy (PTT) has drawn extensively attention. The therapeutic mechanism is the use of photothermal agents (PTAs) in the treatment of tumors,and its therapeutic effect happens only at the tumor site where both light-absorbent and localized laser radiation coexist. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2021 Category: Cancer & Oncology Source Type: news

Tool helps predict who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 12, 2021 Category: Universities & Medical Training Source Type: news

Anti-tumor agent from the intestine
(University of W ü rzburg) Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from german universities in W ü rzburg and Marburg reveals. The findings could help improve cancer therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2021 Category: International Medicine & Public Health Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 9, 2021 Category: Universities & Medical Training Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
(University of California - Los Angeles Health Sciences) A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

RaySearch brings RayStation 9 to China
Radiation therapy software developer RaySearch Laboratories has received regulator...Read more on AuntMinnie.comRelated Reading: RaySearch secures $2.2M Swiss contract RaySearch releases update of RayStation software RaySearch, TAE Life Sciences partner on cancer therapy AI algorithm boosts Swedish clinic's workflow RaySearch unveils new RayStation release (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2021 Category: Radiology Source Type: news

Cancer therapy: Integration of reactive oxygen species generation and prodrug activation
(Compuscript Ltd) https://doi.org/10.15212/bioi-2021-0011Announcing a new article publication for BIO Integration journal. In this article the authors Xiao'en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang from Tianjin University, Tianjin, China discuss the integration of reactive oxygen species generation and prodrug activation for cancer therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news

Reactive oxygen species (ROS): Key components in cancer therapies
(Bentham Science Publishers) This review highlights the genesis of ROS within cells by various routes and their role in cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 30, 2021 Category: Cancer & Oncology Source Type: news

Study sheds light on persistent racial disparities in prostate cancer care in the United States
(NYU Langone Health / NYU Grossman School of Medicine) Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to get them than non-Black men. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2021 Category: Cancer & Oncology Source Type: news

Moffitt receives $10.2 million grant to develop new lung cancer therapies
(H. Lee Moffitt Cancer Center& Research Institute) The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984). The grant, which will provide more than $10.2 million over five years, will support team research with a focus on investigating lung cancer metabolism. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

NYUAD study finds protein aggregation inhibitor can be used to develop cancer therapies
(New York University) A new study provides important insights into the p53 protein, a critical tumor suppressor often mutated and deactivated in cancer, and a key target in the development of cancer therapeutics. Using protein mimetics (small molecules that mimic proteins) originally designed to prevent aggregation of proteins associated with Alzheimer's disease and type II diabetes, the researchers were able to breakdown p53 aggregates and reactivate the protein, leading to the death of cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2021 Category: Cancer & Oncology Source Type: news

Makowski, Pierre publish findings on obesity and response to cancer therapy
(University of Tennessee Health Science Center) Liza Makowski, PhD, professor in the Department of Medicine and the UTHSC Center for Cancer Research, has long been interested in how the immune system is altered by obesity and how this impacts cancer risk and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2021 Category: International Medicine & Public Health Source Type: news

Georgia firm, UT Health SA to develop new cancer therapy and research center
The multistory facility will offer patients an alternative to conventional radiation treatment. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 24, 2021 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

RaySearch secures $2.2M Swiss contract
Radiation therapy software developer RaySearch Laboratories has secured a $2.2 millio...Read more on AuntMinnie.comRelated Reading: RaySearch releases update of RayStation software RaySearch's new planning system treats 1st patients in Japan Canon Medical, RaySearch expand partnership RaySearch, TAE Life Sciences partner on cancer therapy AI algorithm boosts Swedish clinic's workflow (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2021 Category: Radiology Source Type: news

Tmunity enacts layoffs after deaths of 2 patients halt study of experimental prostate cancer therapy
Tmunity is attempting to adapt CAR T-cell therapy, which has proven to be effective in certain blood cancers, for use in patients with solid tumors. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 18, 2021 Category: Biotechnology Authors: John George Source Type: news

Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
(European Society for Medical Oncology) Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news